Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention.

Otsuka, Tatsuhiko; Ueki, Yasushi; Kavaliauskaite, Raminta; Zanchin, Thomas; Bär, Sarah; Stortecky, Stefan; Pilgrim, Thomas; Valgimigli, Marco; Meier, Bernhard; Heg, Dik; Windecker, Stephan; Räber, Lorenz (2021). Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention. Catheterization and cardiovascular interventions, 98(2), E213-E221. Wiley-Blackwell 10.1002/ccd.29650

Text Otsuka_CatheterCardiovascInterv_2021_epub.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy

OBJECTIVES

We aimed to assess the ischemic and bleeding risks of single antiplatelet therapy (SAPT) with prasugrel compared with standard dual antiplatelet therapy (DAPT) (aspirin plus clopidogrel for 1 year) in patients with chronic coronary syndrome (CCS) treated with new generation drug-eluting stents (DES).

BACKGROUND

To date, data on SAPT with potent P2Y12 inhibitors in the absence of aspirin immediately after PCI are limited.

METHODS

Between January 2009 and November 2019, all CCS patients undergoing percutaneous coronary intervention (PCI) enrolled to the Bern PCI registry were considered for analysis. We performed propensity score matching in a 1:4 fashion to compare patients who received SAPT with prasugrel versus standard DAPT. The primary ischemic endpoint was a composite of cardiovascular death, myocardial infarction, and stroke and the primary bleeding endpoint was BARC 3 or 5 bleeding, both assessed at 1 year.

RESULTS

After propensity score matching, the final study population consisted of 225 patients with SAPT and 889 with DAPT. There was no significant difference in rates of the primary ischemic (5.2% vs. 4.2%, p = .50) or the primary bleeding (1.5% vs. 2.0%, p = .60) endpoints between groups. SAPT was not associated with an increased risk of definite stent thrombosis (0.9% vs. 0.8%, p = .83).

CONCLUSIONS

Among selected CCS patients undergoing PCI with DES, SAPT with prasugrel was not associated with an excess of ischemic events compared with standard DAPT. No difference in bleeding was observed either. The results may serve as the basis for larger trials assessing the potential benefits and risks of SAPT.

Interest & Impact

Downloads

2 since deposited on 30 Mar 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item